Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
AstraZeneca has obtained exclusive rights to develop and market Kyowa Hakko Kirin’s benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD) in 13 Asian countries and regions. Kyowa Kirin said on March 24 that it has…
To read the full story
Related Article
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
- AZ to Commercialize Kyowa Kirin’s COPD Drug in Japan
October 31, 2016
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
BUSINESS
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…